Sedation Methods During Cataract Surgery
Primary Purpose
Phacoemulsification, Cataract
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Midazolam + Ketamine 10 MG/ML: 0.5 ML
Midazolam + Ketamine 10 MG/ML: 1 ML
Midazolam + Normal saline
Sponsored by
About this trial
This is an interventional treatment trial for Phacoemulsification focused on measuring ketamine, midazolam, sedation
Eligibility Criteria
Inclusion Criteria:
- Patients met inclusion criteria if they were between 18- and 80-years-old and undergoing elective cataract surgery performed by a single ophthalmologist (KW).
Exclusion Criteria:
- Patients younger than 18, older than 80, those with a serum creatinine >3 mg/dl, advanced liver disease (liver enzymes twice the normal range or higher), and those with an allergy to any of the study medications were excluded from the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Active Comparator
Active Comparator
Arm Label
Midazolam alone
Midazolam + Ketamine 5 mg
Midazolam + Ketamine 10 mg
Arm Description
Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
Outcomes
Primary Outcome Measures
Eye Mobility During Surgery (See Link to Study Protocol for Scale)
Scale of mobility of eye during surgery rate 0 (no movement) to 3 (movement enough to stop surgery).
Secondary Outcome Measures
Measure of Comfort (See Link to Study Protocol for Scale)
Measure of comfort (0-3; 0=very comfortable to 3=extremely uncomfortable
PACU Length of Stay
This is obtained from the records as time spent in the PACU (Recovery Room) after surgery.
Nausea
Self-reported incidence of nausea. This will be assessed by asking the subjects once (just prior to discharge from the PACU) whether they experienced any nausea while they were in the PACU (Recovery Room) and will be a measurement of the count of participants that experienced nausea during this period
Full Information
NCT ID
NCT03054103
First Posted
February 2, 2017
Last Updated
August 9, 2018
Sponsor
Wake Forest University Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT03054103
Brief Title
Sedation Methods During Cataract Surgery
Official Title
A Comparison of Midazolam vs. Midazolam/Ketamine for Conscious Sedation in Patients Undergoing Phacoemulsification Under Topical Anesthesia
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
May 3, 2016 (Actual)
Primary Completion Date
November 5, 2016 (Actual)
Study Completion Date
November 11, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background: Phacoemulsification is the most common surgical procedure performed in the United States and European Union and sedation is commonly used during phacoemulsification to help alleviate patient anxiety and prevent the patient from interfering with the procedure. The investigators have administered ketamine in addition to midazolam in this regard. To study the effectiveness of this technique, The investigators proposed a study to determine if adding low-dose ketamine to midazolam has any beneficial (or negative) effects on operating conditions, patient satisfaction, and recovery during and after unilateral phacoemulsification procedures performed using topical anesthesia and intravenous (IV) conscious sedation.
Methods: In a free-standing Outpatient Surgery Center, the investigators conducted a randomized, double-masked, 3-arm, prospective comparison of IV midazolam only vs. midazolam with ketamine 5 mg IV vs. midazolam with ketamine 10 mg IV. The investigators then measured a single surgeon's assessment of surgical conditions, self-reported patient satisfaction, postoperative pain score, and duration of postoperative stay. The investigators also analyzed the dose of midazolam required to meet subjective anxiolysis in each group.
Detailed Description
Phacoemulsification is the most common surgical procedure performed in the United States and European Union. In addition, the number of diagnoses of cataracts is expected to double from 25,000,000 in 2010 to 50,000,000 in 2050 while the incidence of phacoemulsification is also increasing. Therefore, any attempt to optimize outcome and efficiency is significant.
Sedation is commonly used during phacoemulsification to help alleviate patient anxiety and prevent the patient from interfering with the procedure. However, a great deal of variation exists in anesthetic management of these cases. Investigators have published use of a number of agents for sedation in the literature. These include midazolam, clonidine, propofol, fentanyl, dexmedetomidine, remifentanil, and oral diazepam. Intravenous (IV) clonidine has a half-life of 9-13 h and increased risk of postoperative hypotension. Propofol causes disinhibition and it has to be titrated during surgery to prevent oversedation. Opioids carry an increased risk of respiratory depression, prolonged sedation, as well as delirium in the elderly. Finally, oral medications do not allow for quick dose adjustments during surgery.
Intravenous midazolam is commonly used for sedation during phacoemulsification and other minor procedures. It has properties as an anxiolytic, muscle relaxant, and it is effective at reducing intraocular pressure. However, anxious patients administered benzodiazepines may require higher doses during cataract surgery which can lead to oversedation or disinhibition with subsequent patient movement. These responses can reduce the patient's ability to follow simple commands which can affect surgical outcome. Additionally, patients who receive too much sedation may fall asleep and wake up startled, similarly compromising the outcome of the surgery.
In the search for additional medications that can improve surgical conditions and patient comfort during phacoemulsification, the investigators explored the use of a medication that can improve analgesia and reduce patient movement during procedures, namely ketamine. Ketamine is an NMDA antagonist with both sedative and analgesic properties and has minimal effects on respiration. Ketamine has been used to premedicate and sedate patients undergoing day care procedures without adverse effects, and patients, typically, remain cooperative albeit being sedated. These properties along with its relatively short elimination half-life of 2 h (compared with 3-4 h for midazolam) make ketamine an attractive agent for sedation during monitored anesthesia care (MAC) for cataract surgery.
The purpose of this study was to determine if adding low-dose ketamine to midazolam has any beneficial (or negative) effects on operating conditions, patient satisfaction, and recovery during and after unilateral phacoemulsification procedures performed using topical anesthesia and IV conscious sedation.
The investigators measured the surgeon's assessment of the participant's cooperation during surgery according to a predetermined Likert scale. The investigators also recorded the following outcome measures regarding each participant's surgery: 1) total dose of midazolam, 2) average time spent in the procedural room, 3) postoperative length of stay (LOS), and 4) average postoperative pain score. The subjects received a survey inquiring about the subjects' comfort and sedation level during surgery. Finally, the investigators recorded the following demographic data for all participants: gender, age, psychiatric diagnoses, and use of CNS, psychiatric, or opioid medications.
Statistical Analysis The investigators used Fisher's exact test for examining data expressed as percentages, and Students t-test for yes/no data, and repeated measures ANOVA for 3 group analysis (LOS, surgical duration). The investigators judged significance at a P-value of 0.05. The investigators utilized a generalized estimated equations (GEE) to fit a logistic model to assess differences in the responses of patients based on amount of ketamine received. The GEE approach can fit models to correlated outcomes, as in the case where subjects had more than one procedure performed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Phacoemulsification, Cataract
Keywords
ketamine, midazolam, sedation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Randomized, controlled, double-masked, three-armed clinical comparison
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
Surgical conditions and patient response not aware of medication given.
Allocation
Randomized
Enrollment
105 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Midazolam alone
Arm Type
Placebo Comparator
Arm Description
Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
Arm Title
Midazolam + Ketamine 5 mg
Arm Type
Active Comparator
Arm Description
Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
Arm Title
Midazolam + Ketamine 10 mg
Arm Type
Active Comparator
Arm Description
Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
Intervention Type
Drug
Intervention Name(s)
Midazolam + Ketamine 10 MG/ML: 0.5 ML
Other Intervention Name(s)
Ketalar
Intervention Description
5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
Intervention Type
Drug
Intervention Name(s)
Midazolam + Ketamine 10 MG/ML: 1 ML
Other Intervention Name(s)
Ketalar
Intervention Description
10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
Intervention Type
Drug
Intervention Name(s)
Midazolam + Normal saline
Other Intervention Name(s)
NS
Intervention Description
Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
Primary Outcome Measure Information:
Title
Eye Mobility During Surgery (See Link to Study Protocol for Scale)
Description
Scale of mobility of eye during surgery rate 0 (no movement) to 3 (movement enough to stop surgery).
Time Frame
Intraoperative, end of operation reported
Secondary Outcome Measure Information:
Title
Measure of Comfort (See Link to Study Protocol for Scale)
Description
Measure of comfort (0-3; 0=very comfortable to 3=extremely uncomfortable
Time Frame
Obtained on the first day after surgery during the subject's routine postoperative check in the Ophthalmology Clinic.
Title
PACU Length of Stay
Description
This is obtained from the records as time spent in the PACU (Recovery Room) after surgery.
Time Frame
This will occur one time only, in a range of 20 to 30 minutes after the surgery is completed.
Title
Nausea
Description
Self-reported incidence of nausea. This will be assessed by asking the subjects once (just prior to discharge from the PACU) whether they experienced any nausea while they were in the PACU (Recovery Room) and will be a measurement of the count of participants that experienced nausea during this period
Time Frame
This will occur from time of entry into PACU to time of departure after their surgery. (One time only, in a range of 20 to 30 minutes after surgery.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients met inclusion criteria if they were between 18- and 80-years-old and undergoing elective cataract surgery performed by a single ophthalmologist (KW).
Exclusion Criteria:
Patients younger than 18, older than 80, those with a serum creatinine >3 mg/dl, advanced liver disease (liver enzymes twice the normal range or higher), and those with an allergy to any of the study medications were excluded from the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy N Harwood, MD
Organizational Affiliation
Wake Forest University Health Sciences
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sedation Methods During Cataract Surgery
We'll reach out to this number within 24 hrs